

Certificate of Analysis Cannabinoids

Description I: UT FS Pills 1:100:50 Client: UNIQUE THERAPEUTICS INC.
Sample date: ----- Sample ID: A2800320
Bloomday: ----- Sample material: other
Description II: -----
Further information: -----

| Abbr. | Cannabinoids Advanced | Result | Unit |
|--------|---|--------|---------|
| T-CBD | Total Cannabidiol (CBD + CBDA) | 6,58 | % (w/w) |
| CBD | Cannabidiol | 6,58 | % (w/w) |
| CBDA | Cannabidiolic acid | ND** | % (w/w) |
| T-THC | Total Tetrahydrocannabinol (THC + THCA) | 0,02 | % (w/w) |
| D9THC | D9-Tetrahydrocannabinol | 0,02 | % (w/w) |
| THCA | Tetrahydrocannabinolic acid | ND** | % (w/w) |
| D8THC | D8-Tetrahydrocannabinol | ND** | % (w/w) |
| T-CBG | Total Cannabigerol (CBG + CBGA) | 3,36 | % (w/w) |
| CBG | Cannabigerol | 3,36 | % (w/w) |
| CBGA | Cannabigerolic acid | ND** | % (w/w) |
| CBN | Cannabinol | ND** | % (w/w) |
| CBNA | Cannabinolic Acid | ND** | % (w/w) |
| CBC | Cannabichromene | ND** | % (w/w) |
| CBCA | Cannabichromenic Acid | ND** | % (w/w) |
| CBDV | Cannabidivarin | 0,03 | % (w/w) |
| CBDVA | Cannabidivarinic Acid | ND** | % (w/w) |
| CBL | Cannabicyclol | ND** | % (w/w) |
| CBLA | Cannabicyclolic Acid | ND** | % (w/w) |
| THCV | Tetrahydrocannabivarin | ND** | % (w/w) |
| THCVA | Tetrahydrocannabivarinic Acid | ND** | % (w/w) |
| 9R-HHC | 9R-Hexahydrocannabinol | ND** | % (w/w) |
| 9S-HHC | 9S-Hexahydrocannabinol | ND** | % (w/w) |
| HHCP | Hexahydrocannabiphorol* | ND** | % (w/w) |
| H4CBD | Tetrahydrocannabidiol* | ND** | % (w/w) |

Sample received: 15/01/2025 - 3,211 g



Comment: One product unit contains 48,7 mg CBD, 0,2 mg THC, 24,9 mg CBG.

Head of Laboratory Services



Ing. Christian Fuczik, Chemist

Analysis reviewed - last changes: 17/01/2025 at 10:56

Footnote:

*) Stereoisomeres results on request. **) ND =not detectable. The measured value was below the limit of detection of 0.01 % or 100 mg/kg. The expected measurement uncertainty varies with substance and concentration and can be assumed to be a maximum of 10 %.

For the calculations of the equivalent sums, the respective acid forms were multiplied by the factor 0.877 or 0.878 to conclude the equivalent amount of the neutral form.

Analytical methods: HPLC-DAD, GC-FID and GC mass spectrometry (European Pharmacopoeia: 2.2.28, 2.2.29 and 2.2.43).

This Certificate of Analysis may only be reproduced as a whole and not in parts. Any alteration is punishable under § 223 StGB (Austrian Penal Code) (forgery of documents).